AlphAIAlphAI — Financial news for AI agents
investing.com$AGL

StoneX raises agilon health stock price target to $145 on guidance

StoneX raised its price target for Agilon Health (NYSE:AGL) to $145 from $140, maintaining a Buy rating. The company increased its fiscal 2026 AEBITDA guidance to $145M-$155M, up from $85M. Agilon's Q3 2026 earnings of $1.97 per share beat estimates, with revenue at $1.51B. The stock has gained 634% over the past year, trading at $113.86.

Original reporting
investing.com
Published Nov 11, 2026, 2:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 3:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AGL
Bullish
high confidence
Mentioned
$AGL
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AGLBullishMed
01

Why it matters

The new guidance and target may attract buying interest, but investors should monitor execution risk.

02

Market read

AGL's upgraded guidance and higher price target provide a fresh catalyst for the stock, potentially driving short‑term upside.

03

What to watch

Potential regulatory changes or payer reimbursement pressures could offset the projected AEBITDA growth.

Relevance 7/10Novelty 7/10Timing: today

Background

StoneX analysts updated their model after Agilon Health's quarterly results and raised both guidance and price target.

Company-level read

Ticker impact

$AGLBullishHigh confidence
Context

StoneX raised its price target on Agilon Health (AGL) to $145 and highlighted the company's upgraded fiscal 2026 AEBITDA guidance.

Expected impact

likely upward pressure as investors price in the higher guidance and target.

Evidence & confidence

Guidance lift from $85M to $145-$155M and a new $145 price target represent material new information.

Market effects

Sector

Improved outlook for the health‑care services sector may lift peers with similar payer‑contracting models.

Regional

U.S. health‑care stocks could see modest gains as the guidance beat expectations.

Global

Limited to U.S. markets; no direct global macro effect.

Counterpoint

What could challenge this read

If the guidance upgrade is overly optimistic, the stock could face a pull‑back once earnings materialize.

Key entities

  • company
    Agilon Health Inc.

    U.S. health‑care services provider (NYSE:AGL).

  • analyst
    StoneX

    Research firm that issued the price‑target upgrade.

Read at source← All news

Related articles

$AGLMed

Agilon Health Inc (AGL) (Q3 2026) Earnings Call Highlights: Guidance Raised as Adjusted

Agilon Health Inc (AGL) reported Q3 2026 earnings, beating guidance with adjusted EBITDA of $64M, up from -$91M in Q3 2025. The company raised full-year 2026 guidance and expects 40-50% ACO membership growth in 2027. However, Medicare Advantage membership declined 10% YoY, and medical costs remain high. The company plans to expand into new markets starting in 2028. AGL ended Q3 with $312M in cash and raised its year-end cash outlook to at least $175M.

finance.yahoo.com
$AGLMed

Agilon Health Q3 Earnings Call Highlights

Agilon Health (NYSE: AGL) reported a medical services expense ratio of 88.5% in Q3, down from 104% a year earlier. The company exceeded adjusted EBITDA guidance by $64M, citing favorable risk adjustments and cost trends. Agilon raised its full-year cash outlook to at least $175M and expects 40-50% ACO membership growth in 2027. CEO Tim O'Rourke highlighted clinical program expansions and plans for new market partnerships.

finance.yahoo.com
$AGLHighAI 8/10

Agilon: Q3 Earnings Snapshot

Agilon Health Inc. (AGL) reported Q3 net income of $34.9M, or $1.97 per share, beating analyst expectations of a loss. Revenue was $1.52B, also exceeding forecasts. The company expects full-year revenue between $5.87B and $5.89B. Shares have increased fivefold in the past year, closing at $95.76 on Wednesday.

finance.yahoo.com
$AGLMed

agilon health, inc. (AGL): Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year Increases Full Year 2026 Guidance to Reflect Positive Third Quarter Results

agilon health, inc. (AGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 agilon health Reports Third Quarter 2026 Results Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year Increases Full Year 2026 Guidance to Reflect Positive Third Quarter Results Westerville, O.H., November 4, 2026 – agilon health, inc.

SEC EDGAR 8-K